➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
AstraZeneca
Moodys
Johnson and Johnson
Express Scripts

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,540,382

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,540,382
Title:Crystalline forms of a Bruton's tyrosine kinase inhibitor
Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Purro; Norbert (Los Gatos, CA), Smyth; Mark (Foster City, CA), Goldman; Erick (Concord, CA), Wirth; David D. (Oak Ridge, NC)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:14/405,317
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,540,382
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 9,540,382

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No   Start Trial   Start Trial TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA   Start Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No   Start Trial   Start Trial TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA   Start Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No   Start Trial   Start Trial TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,540,382

PCT Information
PCT FiledJune 03, 2013PCT Application Number:PCT/US2013/043888
PCT Publication Date:December 12, 2013PCT Publication Number: WO2013/184572

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKinsey
Medtronic
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.